Sign in
CompletedEarly phase 1

Pioglitazone for Idiopathic Gastroparesis

Key facts

Who runs it
Johns Hopkins University
Where
Baltimore, United StatesSee the site
Trial code
Status
Completed
Phase
Early phase 1
People taking part
14 people enrolled
Started
24 Oct 2019
Ended
18 Mar 2025
Type of study
Interventional
Treatments tested
  • Pioglitazone 30 mg
Record updated
30 April 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Age 18 years or older at registration
  • Diagnosis of gastroparesis as documented by gastric emptying scintigraphy (4-hour emptying after a low-fat meal with any combination of 2 and 4 hour retention of >60% and 10% respectively)
  • Ongoing symptoms referable to gastroparesis (i.e. Nausea and vomiting, bloating, and abdominal pain)
  • Exclusion of other causes of symptoms such as mechanical gastrointestinal obstruction, uncontrolled esophagitis, peptic ulcer disease, etc. By standard radiographic or endoscopic tests
  • Females will be required to use adequate contraceptive methods during study participation as determined by the Principal Investigator and the study team members

Who cannot take part

  • Previous surgery of the upper gastrointestinal tract, including vagotomy
  • Concurrent use of: estradiol, ethynyl estradiol, mestranol, pazopanib, warfarin, digoxin, atorvastatin, ranitidine, gemfibrozil, fexofenadine, midazolam
  • Another active disorder, which could explain symptoms in the opinion of the investigator
  • Another active disorder, which could explain symptoms in the opinion of the investigator
  • Serious systemic disease, such as recent myocardial infarction/unstable angina, decompensated congestive heart failure, severe pulmonary disease with dyspnea at rest, or altered mental status from any cause
  • Contraindications to pioglitazone such as hypersensitivity or allergy
  • Any other condition, which in the opinion of the investigator would impede compliance or hinder the completion of the study
  • History of bladder cancer or family history of bladder cancer
  • Failure to give informed consent
  • Significant hepatic injury as defined by significant alanine aminotransferase (ALT) and aspartate aminotransferase (AST) elevations of greater than 2 x upper limit of normal (ULN) or a Child-Pugh score of 10 or greater
  • Diabetes as defined by HbA1c >6.5 and/or fasting blood sugar of >125 mg/DL
  • Age < than 18 years
  • Pregnancy or nursing
  • Use of narcotics more than 3 days per week

Where in United States

  • Johns Hopkins Bayview Medical CenterBaltimore, United States

About the trial

What the trial wants to find out

The principal objective of this pilot study will be to evaluate whether 8 weeks of treatment of pioglitazone will improve symptoms as measured by the Gastrointestinal Symptom Index (GCSI) in patients with Idiopathic Gastroparesis.

The group in the trial

  • PioglitazoneTreatment being tested

    Candidates who after the screening period are eligible to receive Pioglitazone

    Treatment: Pioglitazone 30 mg

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Pioglitazone for the Treatment of Idiopathic Gastroparesis (PIOGAS Study)
Record updated
30 April 2025